Aadi Bioscience (AADI)
(Delayed Data from NSDQ)
$1.84 USD
+0.03 (1.43%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $1.84 0.00 (0.00%) 5:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AADI 1.84 +0.03(1.43%)
Will AADI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AADI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AADI
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
AADI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Other News for AADI
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Aadi Bioscience (AADI) Receives a Hold from H.C. Wainwright
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Aadi Bioscience presents new subgroup analysis in advanced malignant PEComa
TD Cowen Keeps Their Buy Rating on Aadi Bioscience (AADI)